Literature DB >> 9152489

Experimental study of combination of extraaortic balloon counterpulsation and ventricular assist cup to acute heart failure in dogs.

A Mitsumaru1, R Yozu, Y Inoue, S Tanaka, H Yoshito, K Kanda, Y Tsutsui, N Tsutsui, S Kawada.   

Abstract

The goal of this study is to evaluate the applicability and effectiveness of combination support of the extraaortic balloon (EAB) and the ventricular assist cup (VAC) to the acute heart failure model. Under general anesthesia, 10 adult dogs were used. Through the median sternotomy, EAB was placed around the ascending aorta and VAC in the pericardial cavity. After heart failure was induced by administration of propranolol, the on-off tests of devices were done as follows. Only EAB was used, and only VAC was used and both devices were used. Regional blood flows (RBFs) of both ventricles, liver kidneys, and brain were measured by colored microsphere technique. Hemodynamic parameters were also measured. In heart failure model, cardiac output (CO) decreased to 66% of control value. In the group assisted by EAB, aortic peak-diastolic pressure and RBFs of both ventricle and brain increased significantly. In the group assisted by VAC, CO and RBFs of all but the left ventricle significantly increased. In the group assisted by EAB and VAC, aortic peak-diastolic pressure, CO, and all five RBFs significantly increased. These results suggest the combination of EAB and VAC is applicable and effective and would be a promising implantable device for the chronic heart failure.

Entities:  

Mesh:

Year:  1997        PMID: 9152489

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  1 in total

1.  Synergistic and Attenuating Effect of Electroacupuncture on Aconitine in Improving Heart Failure and Its Calcium Regulation Mechanism.

Authors:  Chen Zhou; Mo-Zheng Wu; Qun Liu; Juan-Juan Xin; Shuang Wu; Yu-Xue Zhao; Wen-Xi Zhang; Xiao-Chun Yu; Jun-Hong Gao
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-14       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.